AzTrials
AzTrials

GlaucomaSPARCSNCT02627339

Building a Database of Results From People Without Eye Problems

An observational study of Glaucoma, run by Wills Eye at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to build a database of results from a new test that measures contrast sensitivity (the Spaeth-Richman Contrast Sensitivity Test (SPARCS)). Contrast sensitivity is an important part of your ability to see. Read more about this study

Who is it for?
Ages 10 to 90 yearsHealthy volunteers can take part
Conditions the study is for
Glaucoma
How many people
208 participants
Where
1 siteUnited States
Study dates
Aug 2012to Aug 2015
How long will I take part?
1 Day
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 10 to 90 years
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult, Older adult

Study population: Healthy controls with no eye diseases

Who may be able to join

  • 10 years or older and healthy
  • No eye diseases

Who cannot join

  • Patients with glaucoma, macular degeneration, diabetic retinopathy, corneal disease, eye movement disorders or any eye disease causing vision loss
  • Patients with visual acuity worse than 20/40
  • Patients with cataracts or opacities 2+ or greater
  • Patients with refractive error +6 -6 or greater

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Wills Eye Glaucoma Service

    Philadelphia, Pennsylvania, 19107

Other trials in United States

About this study

Official title: A Prospective Study of Controls to Build a Normative Database for the Spaeth/Richman Contrast Sensitivity Test (SPARCS)

The purpose of this study is to build a database of results from a new test that measures contrast sensitivity (the Spaeth-Richman Contrast Sensitivity Test (SPARCS)). Contrast sensitivity is an important part of your ability to see. When contrast sensitivity decreases, you are less able to see objects and detect motion. For instance, if you have decreased contrast sensitivity, you might be less able to read, see in the dark, drive, hit a ball, or walk safely. Decrease in contrast sensitivity leads to a decrease in quality of life.

Read the detailed description

Objective: To build a normative database for the Spaeth / Richman Contrast Sensitivity Test (SPARCS).

Background: Patients with glaucoma have diminished contrast sensitivity. SPARCS is a novel test designed to determine the contrast threshold in the central 5 degrees of vision as well as each of the 4 peripheral quadrants (superotemporal, superonasal, inferotemporal, inferonasal). It is performed on a standard computer with at least 1024 x 768 monitor resolution. The correct testing distance is 50 cm away from the computer screen. Appropriate refractive correction is used. Testing is performed in a room with standardized lighting (85 cd / m2) and no windows in order to minimize glare and reflections. Testing is performed monocularly with the non-tested eye covered by an eye patch. The purpose of this study is to build a normative database for SPARCS.

Study Design: Cross sectional observational study.

Methods: Healthy volunteers will be recruited from the Wills Eye Institute after obtaining informed consent following the principles of the Helsinki Convention. Approximately 320 people free of ocular disease will be recruited to form a portion of the normative database for SPARCS. A goal of 20 subjects per decade of life (10-19, 20-29, 30-39, 40-49, 50-59, 60-69, 70-79, 80+) for both Caucasians and African Americans will be recruited. Other ethnicities will also be recruited, though without specific recruitment goals. Future study locations will help diversify the population of the normative database.

After agreeing to participate in the study, subjects will be assessed to determine if they qualify. Potential participants will be asked if they have any known eye diseases or decreased vision. Best-corrected monocular visual acuities will be assessed using an ETDRS visual acuity chart. A slit lamp examination will be performed to confirm good ocular health. Subjects will be excluded if they have any apparent ocular disease that affects visual acuity or visual function. For example, people with glaucoma, macular degeneration, or diabetic retinopathy will be excluded. Additional exclusion criteria includes: visual acuity 20/40 or worse; cataract grade 2 3+ or worse; posterior capsular opacity grade 2 3+ or worse; refractive error greater than +5 or -5 diopters; and incisional eye surgery within the prior 3 months.

After a person qualifies for the normative database, he or she will then take SPARCS. A trained technician will position the patient to the correct testing distance, check room lighting, and then explain the test. Subjects will be told to fixate on the central area and when ready, click the central area once with a computer mouse. Vertical dark bars will briefly appear in 1 of the 5 tested areas on the computer monitor. A subject will then move the mouse to the area the image appeared and click it once. When the subject is ready for the next image to appear, he or she will click again on the central area. Subjects are also instructed to guess where the image appeared if unsure. Vertical square waves of varying contrast levels will then continue to appear in a random pattern until threshold has been reached for each area. After the testing algorithm has been completed, the test will automatically end.

Each eye of an eligible subject will take the test twice after receiving instructions from a technician. The technician will remain in the testing room the first two times SPARCS is taken. A half hour later, the subject will then take SPARCS again without instructions from the technician and without the technician being present in the room.

The mean score and standard deviation of each area and the total score will be analyzed for age, gender, race, and lens status. Spearman correlations will be used to examine continuous variables and Kruskal-Wallis analysis for categorical measures. Test-retest repeatability will be assessed using the Coefficient of Repeatability and the Intraclass Correlation Coefficient.

Conditions
Glaucoma
Keywords
Contrast Sensitivity
Medical subject headings
Glaucoma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT02627339
Study groupRoleWhat they receive
Healthy controlsHealthy controls age 10 to 90 years

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. SPARCS results

    Results from each eyes response to the contrast sensitivity test

    Measured: 1 day

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Dec 2015 (estimated)
  2. Study startAug 2012
  3. Primary completionAug 2015
  4. Study completionAug 2015

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
208 participants (actual)
Target duration
1 Day
IDs, dates and publications
ClinicalTrials.gov ID
NCT02627339
Sponsor's protocol ID
12-234E
Acronym
SPARCS
Status last verified
Nov 2016
First submitted
8 Dec 2015
Last updated
21 Nov 2016
Results posted
No
Data monitoring committee
No
Individual data sharing
No

Publications

  • Richman J, Spaeth GL, Wirostko B. Contrast sensitivity basics and a critique of currently available tests. J Cataract Refract Surg. 2013 Jul;39(7):1100-6. doi: 10.1016/j.jcrs.2013.05.001. Epub 2013 May 23.

    PubMed 23706926

Questions about this trial

What is this clinical trial studying?

An observational study of Glaucoma, run by Wills Eye at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 21 Nov 2016. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

SPARCS results (time frame: 1 day). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02627339, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Nov 2016.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in